某铝电公司自2016年对现有300 kA、350 kA、400 kA 3个系列进行技术路线创新实践,形成了铝电解生产“4221”精准管控技术。随着阶梯电解政策的实施,形成了成熟的铝电解生产“4221”工艺技术路线。近6年的生产实践证明,本工艺技术路线大...某铝电公司自2016年对现有300 kA、350 kA、400 kA 3个系列进行技术路线创新实践,形成了铝电解生产“4221”精准管控技术。随着阶梯电解政策的实施,形成了成熟的铝电解生产“4221”工艺技术路线。近6年的生产实践证明,本工艺技术路线大幅降低管理难度,较行业平均水平电流效率提高2%以上、电解槽寿命提高400天以上、原铝质量Al99.85率提高30%以上,并降低铝液交流电耗100 kWh/t以上,同时降低工人劳动强度、劳动量50%以上。本工艺技术路线为铝电解行业高效稳定运行问题,提供了解决思路。本工艺技术路线经济效益、社会效益显著。展开更多
Cancer immunotherapies, which train the natural immune system to specifically kill tumor cells while sparing the healthy cells,have helped revolutionize cancer treatments and demonstrated promising clinical therapeuti...Cancer immunotherapies, which train the natural immune system to specifically kill tumor cells while sparing the healthy cells,have helped revolutionize cancer treatments and demonstrated promising clinical therapeutic benefits for decades. However, the therapeutic outcome of immunotherapies, even for the most successful immune checkpoint blockade(ICB) therapy, remains unsatisfactory in the clinical practice, mainly due to the low immunogenicity of solid tumors and its immunosuppressive tumor microenvironment(TME). Notably, several cancer treatment modalities, including chemotherapy, radiotherapy, and phototherapy, have been revealed to evoke tumor immunogenicity and reverse immunosuppressive TME via inducing immunogenic cell death(ICD) of tumor cells, which synergistically sensitized tumors to ICB therapy. Nanomedicines have been extensively applied to augment ICD-inducing treatment modalities and potentiate ICB therapeutic efficacy therapy due to the opportune convergence of immunotherapy and nanotechnology. Here, we discuss the recent advances in nanomedicine-mediated ICD and its combination with ICB therapy.展开更多
基金supported by the National Natural Science Foundation of China (Grant Nos. U22A20156, 52173121)the Open Project of Guangdong Province Key Laboratory of Biomedical Engineering (Grant No. GDKLBEM202203)。
文摘Cancer immunotherapies, which train the natural immune system to specifically kill tumor cells while sparing the healthy cells,have helped revolutionize cancer treatments and demonstrated promising clinical therapeutic benefits for decades. However, the therapeutic outcome of immunotherapies, even for the most successful immune checkpoint blockade(ICB) therapy, remains unsatisfactory in the clinical practice, mainly due to the low immunogenicity of solid tumors and its immunosuppressive tumor microenvironment(TME). Notably, several cancer treatment modalities, including chemotherapy, radiotherapy, and phototherapy, have been revealed to evoke tumor immunogenicity and reverse immunosuppressive TME via inducing immunogenic cell death(ICD) of tumor cells, which synergistically sensitized tumors to ICB therapy. Nanomedicines have been extensively applied to augment ICD-inducing treatment modalities and potentiate ICB therapeutic efficacy therapy due to the opportune convergence of immunotherapy and nanotechnology. Here, we discuss the recent advances in nanomedicine-mediated ICD and its combination with ICB therapy.
